Opiant Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Opiant Pharmaceuticals generated cash of $1,926,489, which is more than the previous year. Cash used in financing activities reached the amount of $2,718,940 last year. Net change in cash is therefore -$10,397,389.
Cash Flow
| 2012 | -1.09M | 0 | 1.06M |
|---|---|---|---|
| 2013 | -747.3K | 0 | 1.32M |
| 2014 | -1.00M | 0 | 661.47K |
| 2015 | -4.23M | 0 | 4.41M |
| 2016 | -915.28K | -7.53K | 1.97M |
| 2017 | 5.55M | 0 | -165K |
| 2018 | -522.97K | 0 | 17.02M |
| 2019 | 4.06M | -302.47K | 2.60M |
| 2020 | -2.02M | -50.88K | 19.36M |
| 2021 | 1.92M | -15.01M | 2.71M |
OPNT Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 48.25M | 30.98M | 24.61M | 8.11M | 1.48M | 434.21K | 254.77K | 598.62K | 20.42K | 51.78K |
Operating activities | ||||||||||
Net income | 3.00M | -1.86M | 11.59M | -21.19M | 6.58M | -7.81M | -7.03M | -11.48M | -4.65M | 0 |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 661.53K | 608.47K | 237.78K | 2.55K | 5.14K | 2.38K | 1.37K | 1.37K | 1.37K | 1.37K |
Stock-based compensation expense | 2.74M | 2.27M | 3.19M | 0 | 0 | 0 | 0 | 0 | 2.34M | 11.23M |
| Deferred income tax benefit | 2.74M | 2.27M | 3.19M | 0 | 0 | 0 | 0 | 0 | 2.34M | 11.23M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -4.41M | -1.69M | -2.72M | 7.20M | -3.43M | -312.49K | 0 | 0 | 0 | 0 |
Inventories | -313.69K | -2.45M | -8.28M | 8.52M | -1.32M | 522.92K | 0 | 0 | 0 | 0 |
Accounts payable | 308.13K | 1.63M | 361.22K | -1.92M | 2.07M | -174.87K | 114.85K | 159.83K | -14.73K | -48.63K |
Cash generated by operating activities | 1.92M | -2.02M | 4.06M | -522.97K | 5.55M | -915.28K | -4.23M | -1.00M | -747.3K | -1.09M |
Investing activities | ||||||||||
Purchases Of Investments | -15.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -50.88K | -302.47K | 0 | 0 | -7.53K | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -15.01M | -50.88K | -302.47K | 0 | 0 | -7.53K | 0 | 0 | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | 20K | 0 | 0 | 17.15M | 190.42K | 1.18M | 311.66K | 213.96K | 55K | 802.92K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | -281.19K | 0 | 0 | 0 | -171.55K |
Cash used in financing activities | 2.71M | 19.36M | 2.60M | 17.02M | -165K | 1.97M | 4.41M | 661.47K | 1.32M | 1.06M |
Net Change In Cash | -10.39M | 17.27M | 6.36M | 16.49M | 5.39M | 1.04M | 179.44K | -343.85K | 578.2K | -31.36K |
Cash at end of period | 37.85M | 48.25M | 30.98M | 24.61M | 6.87M | 1.48M | 434.21K | 254.77K | 598.62K | 20.42K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |